Compare Monster Beverage Corp (MNST) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs GeneDx Holdings Corp — how do they compare? Monster Beverage Corp trades at $94.22 (market cap $93.35B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Monster Beverage Corp is far larger — about 51.9× GeneDx Holdings Corp's market cap, and Monster Beverage Corp is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| MNST | WGS | |
|---|---|---|
Market Cap | $93.35B | $1.80B |
Sector | Consumer Staples | Technology |
52-Week High | $99.94 | $167.51 |
52-Week Low | $58.75 | $34.51 |
Enterprise Value | $91.65B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $94.46, down 3.12% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.58 exceeding the $0.527 estimate, and maintains robust profitability with a net income margin of 23.11%. A 2-for-1 stock split is scheduled for August 2026, reflecting confidence in future growth.
The investment outlook is positive, driven by consistent earnings outperformance, international expansion, and product innovation. Risks include elevated valuation multiples (P/E of 46.11) and competitive pressures in the beverage sector. Analyst consensus is bullish with a $97.83 price target, suggesting modest upside from current levels.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
